Replies to post #555952 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

NICE told me May 11 2022:

It is important to note that we can only appraise drugs that have a marketing authorisation for the treatment of a particular indication or are expected to receive one during our appraisal process, and can only issue final guidance on drugs that have a marketing authorisation.

 

[manibiotech]

And can you help us provide a reason of not disclosing what they can on only one occasion a year when CEO somewhat addresses the shareholders

[exwannabe]

NICE only reviews a drug after it's been approved by MHRA. They don't have NHS subsidize drugs which are not approved by MHRA. So given NICE are already involved in determining if they will reimburse the cost of DCVax, I believe the firm are well ahead of what they disclosed at the 2022 ASM.

This same was being said 5 years ago when the NICE process was farther ahead than it is today.

The reality is that NICE starts the process in advance as it takes a long time.

The NICE process is mostly public. At some point they will send out a meeting invite for the actual evaluation. If NWBO actually is able to document their case, then the technical evaluation happens.

5 years ago NICE sent out the invite and NWBO said they could not make it.